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Commentary
In just 15 years the mobile phone has evolved 
from an uncommon, expensive, brick-shaped 
object used in restricted areas of Western 
countries to a convenient and ubiquitous part 
of modern life, with > 4.6 billion subscriptions 
worldwide (International Telecommunication 
Union 2010). The arrival of this mass tech-
nology has been accompanied by some pub-
lic and media concern about the possibility 
that the radiofrequency (RF) fields emitted 
by the phones might cause cancer, especially 
brain tumors. Numerous committees have 
considered the evidence and recommended 
more research (Independent Expert Group on 
Mobile Phones 2000; Scientific Committee 
on Emerging and Newly Identified Health 
Risks 2009). Since 1999, a series of epidemi-
ologic studies of mobile phone use and can-
cer have been published, mainly focused on 
brain tumor risks. Collectively, they have not 
provided evidence of a relationship, but they 
have had sufficient limitations to leave the 
question unresolved (Ahlbom et al. 2009).
The Interphone study was launched 
in 2000 to provide a more powerful and 
methodologically rigorous investigation of 
this issue by collecting data in 13 countries. 
Now, 10 years and €19 million later, after 
much anticipation and a lengthy delay, the 
key results on brain tumors have been pub-
lished (Interphone Study Group 2010). What 
should be made of them, considered along 
with the rest of the literature? Do we now 
know whether mobile phones cause brain 
tumors? If not, how much closer are we to 
knowing?
The Interphone Study
The Interphone study was an international, 
coordinated interview case–control study inves-
tigating the potential effect of mobile phone 
use on the risk of the two most common types 
of brain tumor, glioma and meningioma (and, 
although not yet published, also acoustic neu-
romas and parotid gland tumors). The study 
used a common core questionnaire and to some 
extent a common core protocol, but deviations 
and additions were allowed; for instance, cases 
were population based in most countries but 
hospital based in Japan and France, and controls 
were pair matched at nine centers but stratum 
matched in the other seven. These methodo-
logical inconsistencies add to the difficulty of 
interpreting the overall results. Nevertheless, 
the multicenter structure enabled a study of 
exceptional size: > 5,000 patients with these 
relatively uncommon tumors were interviewed 
in a 5-year period—a considerable feat.
The study questionnaire asked in detail 
about the type and pattern of use of each 
mobile phone the respondent had used and 
about other RF exposures and brain tumor 
risk factors. The questionnaire was adminis-
tered by an interviewer using a computerized 
laptop data entry system (except in Finland), 
with practical advantages but with the disad-
vantage that no original paper records were 
available to check the fidelity of data entry for 
apparently erroneous values. The questionnaire 
collected information on hands-free phone 
use, which was excluded from analyses because 
head exposure would then be negligible. It 
is unknown, however, how well subjects can 
recall past use of hands-free devices or whether 
recall differed between cases and controls.
The analyses employed post hoc matching 
of one control per case (two for Germany) for 
the centers that had used a stratified control 
selection. The individual matching was then 
used for the analyses. This resulted in loss of 
data: 70 cases and > 2,000 interviewed con-
trols were not included in the final analyses. 
Furthermore, most of the national studies that 
contributed to Interphone covered a wider 
age range (as low as 18 and/or up to 69 years) 
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sibility that mobile phones might cause cancer, especially brain tumors.
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of the largest epidemiologic study yet: the 13-country Interphone Study.
discussion: Methodological deficits limit the conclusions that can be drawn from the Interphone 
study, but its results, along with those from other epidemiologic, biological, and animal studies and 
brain tumor incidence trends, suggest that within about 10–15 years after first use of mobile phones 
there is unlikely to be a material increase in the risk of brain tumors in adults. Data for childhood 
tumors and for periods beyond 15 years are currently lacking.
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increasingly against the hypothesis that mobile phone use can cause brain tumors in adults.
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than the Interphone analyses (30–59 years), so 
a considerable proportion of the national data 
[e.g., 58% for Sweden (Lönn et al. 2005)] was 
not included in the overall pooled analyses. 
The national publications need to be consid-
ered, therefore, as additional semi-independent 
sources of evidence, not simply as subsets of 
the overall Interphone analysis.
The Interphone publication (Interphone 
Study Group 2010) compared 2,708 glioma 
cases diagnosed at 30–59 years of age dur-
ing 2000–2004 with 2,972 controls, and 
2,409 meningioma cases with 2,662 controls. 
Participation rates were 64% for glioma cases, 
78% for meningioma cases, and 53% for con-
trols, with considerable variation among study 
centers; proxies were used for 13% of glioma 
cases, 2% of meningioma cases, and 1% of con-
trols. Sensitivity analyses did not suggest, how-
ever, that the results depended on participation 
rates across centers or on inclusion of proxies.
Key findings were a significantly dimin-
ished risk of both glioma and meningioma in 
regular users compared with people who were 
not users or were occasional users (“  non  users”); 
no trend in risk of either tumor type with 
cumulative hours of use but an apparent raised 
risk of glioma, and to a lesser extent menin-
gioma, in those in the top decile of cumula-
tive hours of use; and no relation of risk of 
either tumor type to cumulative number of 
calls, years of use, or years since first use. These 
results raise several important issues.
Reduced Risk of Brain Tumors 
in Mobile Phone Users
The Interphone Study, as well as some previous 
case–control studies (Inskip et al. 2001; Muscat 
et al. 2000) and the only large cohort study 
(Schüz et al. 2006), identified a reduced risk of 
brain tumors among mobile phone users com-
pared with non  users. In the Interphone study as 
a whole, ever-regular use was associated with an 
odds ratio (OR) of 0.79 [95% confidence inter-
val (CI): 0.68, 0.91] for meningioma and 0.81 
(95% CI: 0.70, 0.94) for glioma. The pattern 
was consistent across the Interphone study sites 
and statistically precise, calling for explanation.
There is empirical evidence that the reduced 
risks were attributable partly to non  response 
bias (Vrijheid et al. 2009). Cases and controls 
who initially declined to participate but agreed 
to complete a short non  response questionnaire 
had lower frequencies of regular mobile phone 
use than did those who participated fully. The 
quantitative results from this non  response 
questionnaire imply that selection bias would 
produce an OR of 0.87–0.92 if the null hypoth-
esis were true. It seems unlikely that differen-
tial response based on mobile phone use could 
explain the diminished risk entirely, because the 
reduction in risk was similar for study centers 
that did and did not reveal to potential partici-
pants the study’s focus on mobile phone use.
Even if the same pattern of diminished 
response by non  users occurred for cases and 
controls, which it did not, the overall greater 
non  participation among controls because of 
refusal would result in a downward bias in 
the OR. Whereas only 11% of glioma and 
meningioma cases refused to participate, 30% 
of controls did so. Furthermore, the phone 
use of those who did not complete even the 
non  response questionnaire (e.g., because of 
refusal or death) is unknown, adding further 
uncertainty to the extent of the overall bias.
Other likely contributors to the dimin-
ished ORs in users are prodromal symptoms 
such as headaches and impaired cognition, 
which may have prevented recent initiation of 
mobile phone use among subjects with as yet 
undiagnosed brain tumors. Thus, some cases 
who would otherwise have become short-term 
users may have remained non  users, leading 
to artifactually reduced ORs for brain tumor 
in phone users, especially short-term users 
(and low cumulative users, because short-term 
use will tend to result in low cumulative use). 
It seems likely that this accounts for at least 
part of the decreased risk in users, because the 
strongest reduction in glioma risk was found 
in the shortest-term users. Other potential con-
tributors to diminished ORs can be hypothe-
sized, but there is no evidence for them [see 
Supplemental Material, p. 1 (http://dx.doi.
org/10.1289/ehp.1103693)].
The appropriate analytic approach and 
interpretation in light of this presumably non-
causal reduction in risk are not obvious. One 
suggested response has been to alter the refer-
ent group, by using low regular use rather than 
non  use plus occasional use as the referent. This 
results in an upward shift in the ORs across the 
board, more for glioma than for meningioma, 
but no change in the magnitude of those 
ORs relative to one another across the range 
of exposure (Interphone Study Group 2010). 
However, whether this decreases or increases 
the bias depends on two factors: whether the 
diminished risk is attributable to non  response, 
and whether the biases apply to low-level users 
as well as non  users. Neither of these factors is 
known, but to the extent that the diminished 
risk is attributable to prodromal symptoms, 
changing the referent group would produce 
upward bias. If short-term users (or low cumu-
lative users) are used as the referent exposure 
group, the more pronounced risk reduction 
in this group caused by prodromal symptoms 
would bias relative risks for long-term users (or 
high cumulative users) upward.
Risks after Prolonged and 
Heavy Mobile Phone Use 
If exposure to RF fields through mobile 
phone use were tumorigenic, people using 
mobile phones longest and those who were 
the heaviest users would be expected to show 
the highest risks of brain tumors. Reliability 
of recall of amount of use a decade ago is 
unknown, and the average amount of use is 
likely to have shifted over time as phone use 
has escalated universally. Validation studies of 
recall of phone use in the previous 6 months, 
and up to approximately 5 years in the past, 
have found that even in the short term, sub-
jects on average underestimate the number 
of calls per month but overestimate dura-
tion of calls, with moderate systematic error 
(underestimation by light users, overestima-
tion by heavy users) and a large amount of 
random error (Vrijheid et al. 2006). Recall of 
number of calls was found to be better than 
recall of their duration. Furthermore, in the 
Interphone study cases more often than con-
trols gave implausibly high estimates of daily 
time spent on calls (e.g., 10 cases and no con-
trols reported average use of > 12 hr/day). A 
validation study that included both cases and 
controls found that cases overestimated phone 
use in distant time periods, which could cause 
positive bias in risk estimates (Vrijheid et al. 
2009). It thus appears that recall of amount 
of use was appreciably erroneous and quite 
likely different for cases than for controls. It 
is possible that recall of year of first use, and 
hence duration of use, may have been more 
reliable than recall of amount of use.
Notwithstanding the inherent unreli-
ability of recalled amount of use, the only 
cumulative mobile phone exposure measures 
available in the Interphone study were dura-
tion and amount. Neither yielded material 
evidence of a positive association with brain 
tumors. Specifically, for the longest-term users 
(≥ 10 years since first use), no association was 
found for glioma (OR = 0.98; 95% CI: 0.76, 
1.26) or meningioma (OR = 0.83; 95% CI: 
0.61, 1.14). Most ORs were < 1.0, and no 
dose–response pattern was found. This is con-
sistent with results from a cohort study based 
on subscriber lists (Schüz et al. 2006) but in 
contrast with the raised risks for long-term use 
reported by Hardell et al. (2006a, 2006b). For 
heavy use measured by estimated total num-
ber of calls, again, there was no positive asso-
ciation with brain tumors: ORs were < 1.0 
in all categories of number of calls, includ-
ing those in the top decile, for both glioma 
and meningioma. For heavy use assessed by 
cumulative duration of calls, again, there was 
no dose–response effect for either type of 
tumor. For glioma, although the risk estimate 
for subjects in the highest decile of total call 
time (≥ 1,640 hr) was modestly raised at OR 
= 1.40 (95% CI: 1.03, 1.89), it was disjointed 
from the risk in the next heaviest users, the 
second highest decile, which had one of the 
lowest risk estimates: OR = 0.71 (95% CI: 
0.53, 0.96). Similarly, for meningioma the 
OR in the highest decile of total call-time OR 
was 1.15 (95% CI: 0.81, 1.62), whereas in the Swerdlow et al.
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next heaviest decile of users it was 0.76 (95% 
CI: 0.54, 1.08). Furthermore, the top decile 
category presented was not actually 10% of 
the control data—it is unknown to what 
extent risk would have been raised in the true 
top decile, or to what extent the raised risk is 
a function of the cut-point chosen (about the 
7th percentile for meningioma and the 8th 
percentile for glioma).
The only previously available risk estimates 
among comparably heavy users are from case–
control studies conducted by Hardell et al. 
(2006a, 2006b) in Sweden, which reported 
a markedly raised risk and positive dose– 
response gradient for “malignant tumors” 
but not for meningioma. We have discussed 
elsewhere why the Hardell et al. results are 
problematic (Ahlbom et al. 2009). Assessment 
of the findings with respect to cumulative 
call time in individual published component 
studies of Interphone, whose participants 
variously covered a wider range of ages than 
Interphone, confirmed the lack of dose– 
response effect with glioma [see Supplemental 
Material, p. 2 (http://dx.doi.org/10.1289/
ehp.1103693)]. Furthermore, for number 
of calls, which validation studies suggest may 
be better reported than cumulative hours of 
exposure, there was no indication of raised 
risk in the top decile or of dose response.
Finally, participants who had been using 
mobile phones the longest (≥ 10 years) and 
had accumulated highest lifetime call hours 
(≥ 1,640 hr) might be expected a priori to 
have been at the highest risk if RF exposure 
were tumorigenic. This was not the case, 
however, for either glioma (OR = 1.34; 95% 
CI: 0.90, 2.01) or meningioma (OR = 0.95; 
95% CI: 0.56, 1.63) (Interphone Study 
Group 2010). Instead, it appeared that the 
very few individuals who started regular use 
only 1–4 years ago yet whose cumulative call 
time fell in the highest decile, because of their 
reported recent heavy use, carried the greatest 
risk of both tumor types: for glioma OR = 
3.77 (95% CI: 1.25, 11.4) and for menin-
gioma OR = 4.80 (95% CI: 1.49, 15.4), with 
no dose response. The similarity of the results 
for meningioma and glioma suggests that 
shared recall bias exists, because such a recent 
use period should have little or no bearing on 
the pathogenesis of meningioma, which tends 
to have a long latent period.
The magnitudes of relative risk of glioma 
and meningioma found in the top decile of 
cumulative use of phones were not large (1.40 
and 1.15, respectively) and are on the margins 
of what epidemiology can detect. It is at a 
level at which the errors and biases identified 
in the study data provide a plausible—in-
deed, at present a more plausible—alternative 
explanation of the findings than does causa-
tion. Furthermore, the analyses were derived 
from a very large number of comparisons 
investigated [some reported by the Interphone 
Study Group (2010), the great majority not]; 
hence, there was the potential for selective 
emphasis in presentation of the results.
In summary, the Interphone study and 
the literature overall have methodological 
deficiencies but do not demonstrate greater 
risk of either glioma or meningioma with lon-
ger or greater use of mobile phones, although 
the longest period since first use examined is 
< 15 years.
Anatomic Distribution 
of the Tumors Compared 
with Anatomic Distribution 
of Exposure 
RF exposure during mobile phone use is 
highly attenuated within a few centimeters 
in the brain, so exposure is largely to the side 
of the brain, and to the anatomic area, closest 
to the antenna. It has been reported that on 
the side of the brain where the phone is used, 
50–60% of the total RF energy is absorbed 
in the temporal lobe, and the average specific 
absorption rate is highest in the temporal lobe 
and the cerebellum (Cardis et al. 2008). Thus, 
examination of location of the tumor in rela-
tion to location of exposure is of interest.
Laterality. If there were a causal associa-
tion between mobile phone use and brain 
tumor risk, one would expect an increased 
risk on the same side of the head as the phone 
is held and a null finding on the opposite 
side. On the other hand, if some brain tumor 
patients believed that mobile phone use had 
caused their tumor, and consequently over-
reported use on the affected side, this would 
result in an apparent risk increase on the same 
side of the head accompanied by a decreased 
risk on the opposite side. (The same bias is 
not possible for controls, who do not have 
a tumor side.) Furthermore, if there were a 
causal relationship, one would expect an effect 
of laterality to occur after a sufficient induc-
tion period, not for solely recent use (unless 
there was a promotional effect of mobile 
phones that was very rapid and substantial, 
which presumably would be easily and rapidly 
detectable from population incidence trends).
ORs for glioma and meningioma in the 
Interphone study tended to be greater in sub-
jects who reported usual phone use on the 
same side of the head as their tumor than on 
the opposite side for most categories of dura-
tion of use, cumulative call time, and cumu-
lative number of calls. Most ipsilateral ORs 
were not above unity, however, and there was 
no dose–response trend, although the great-
est ORs tended to be for the top decile of 
  ipsilateral exposure.
There are currently no validation studies 
of retrospective self-reported side of use, and 
there is no evidence of consistency over time 
in the preferred side of use. Overall, the greater 
risk for reported ipsilateral than contralateral 
use would be compatible with causation or bias 
as an explanation, but the finding that contral-
ateral risks and many of the ipsilateral risks 
were generally below unity, with no consistent 
pattern of greater ipsilateral/  contralateral ratios 
with greater exposure (except for cumulative 
number of calls and risk of glioma), would 
favor bias as the explanation.
Lobe. The risk of glioma in the temporal 
lobe for regular use and for most categories of 
exposure was reduced and did not differ from 
that in other lobes. ORs for long-term use and 
highest cumulative call time, however, were 
somewhat greater in the temporal lobe than 
in other lobes. This is the pattern one would 
expect if there were a causal effect, although 
there was no suggestion of a dose–response 
effect for temporal tumors, which would also 
be expected if there were causality. No coher-
ent pattern was observed for meningioma, for 
which the OR for temporal lobe tumors for 
regular use was somewhat lower than for other 
lobes, and there was no evidence of greater 
risk in the temporal than other lobes in other 
categories of use.
Exact anatomic location of the tumor. 
Interphone collected neuroradiologic infor-
mation on the exact locations of brain tumors 
in the study. Although this has not been 
published for the study overall, it has been 
published for glioma for many of the study 
centers and for meningioma for one center. 
These analyses gave no indication of an associ-
ation of tumor risk to proximity of the tumor 
to the exposure source (Larjavaara et al. 2011; 
Takebayashi et al. 2008).
In summary, among the three types of data 
on anatomic location, the results for laterality 
of phone use are the least interpretable. They 
are compatible with bias, or at least partly with 
causation, but do not give firm evidence for 
either. The evidence on lobe of glioma, but 
not of meningioma, is inconsistently in the 
direction that would be expected with causal-
ity, but not decisively so. The evidence on 
exact location of the tumor, which one would 
expect to give the most rigorous analysis 
because it has greater precision without bias, 
does not support a causal association.
Data on tumor risk in relation to type of 
mobile phone, and hence of exposure, have 
not suggested a relation [see Supplemental 
Material, p. 2 (http://dx.doi.org/10.1289/
ehp.1103693)].
Other Relevant Evidence 
The biological literature on RF and can-
cer does not support an etiologic effect— 
extensive research has not established any 
biological mechanism by which RF fields, 
which are not mutagenic, could cause can-
cer, and animal experiments have given no 
replicable evidence for cancer causation in Mobile phones and brain tumor risk
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animals (Scientific Committee on Emerging 
and Newly Identified Health Risks 2009).
The major biases and uncertainties in 
interpretation of the Interphone study are 
similar to those in other interview-based 
case–control studies of brain tumors and 
mobile phones. The exceptional size of the 
Interphone study has not proved to be a criti-
cal strength—issues of bias and misclassifica-
tion have proved far more important than 
tightness of CIs. Therefore, more studies of 
the same basic design as Interphone, based 
on recall of phone use, no matter how care-
fully designed and conducted, are unlikely to 
add materially to our knowledge. There are 
other epidemiologic designs that do not share 
these weaknesses (although they have others), 
whose results need consideration in relation to 
the uncertainties remaining after Interphone: 
studies of the effects of occupational and resi-
dential RF exposures, record linkage-based 
case–control and cohort studies of phone use, 
and trend analyses of brain tumor incidence 
rates in the general population.
The occupational studies, and those of 
cancer risk in relation to residential proximity 
to RF broadcasting towers, have not indi-
cated any cancer risk, although they have been 
methodologically weak (Ahlbom et al. 2004). 
Studies that have linked private non-
corporate telephone subscription records to 
cancer registry records (in certain Nordic 
countries) (Auvinen et al. 2002; Schüz et al. 
2006) or death records (in the United States) 
(Dreyer et al. 1999) have the strengths that 
they avoid recall bias and misclassification 
and avoid participation bias. They have the 
weaknesses, however, not present in inter-
view case–control studies such as Interphone, 
that the subscription data exclude corporate 
subscriptions, which in the early years were 
likely often to have been held by heavy users, 
and that the named subscriber is not nec-
essarily the user. These problems are likely 
to have diluted any true association. A U.S. 
cohort study (Dreyer et al. 1999) was halted 
1 year after recruitment and so was essen-
tially uninformative. A national records-based 
case–control study in Finland (Auvinen et al. 
2002) based on very short durations of use 
found a borderline significantly raised risk of 
glioma in ever-users, with some evidence for 
a relation to analog not digital phone use. 
A Danish cohort study (Schüz et al. 2006) 
followed 420,000 phone subscribers over a 
period of 7–21 years and gave no indication 
of raised risk of glioma or meningioma or any 
trend in risk with duration since first use.
Trend data. Analyses of secular trends in 
brain tumor incidence, in countries that have 
had good-quality diagnostic facilities and can-
cer registration, can give powerful evidence 
constraining what can reasonably be proposed 
as an etiologic relationship. The dramatic rise 
in mobile phone use over a relatively short 
period of time provides an unusual opportu-
nity to assess the potential for a causal effect 
on cancer occurrence through high-quality, 
unbiased descriptive epidemiologic data. 
Because substantial misclassification is inevi-
table in recall-based exposure information 
from the Interphone interviews, it follows 
that if the raised relative risk observed in the 
top decile of users in the Interphone study 
were caused by phone use, not by chance or 
artifact, then the true effect would likely be 
much larger and therefore more easily detect-
able in population cancer incidence trends. 
However, data from the Nordic countries for 
1974–2003 (Deltour et al. 2009) and chil-
dren in the Nordic countries for 1985–2006 
(Schmidt et al. 2011) and from Switzerland 
for 1969–2002 (Roosli et al. 2007), England 
for 1998–2007 (de Vocht et al. 2011), and 
the United States for 1992–2006 (Inskip 
et al. 2010) and for 1987–2007 (Kohler et al. 
2011) showed no indication of increases in 
brain tumor incidence in relation to the intro-
duction and growing use of mobile phones, 
up to 20 years after their introduction and 
10 years after their use became widespread.
This does not appear compatible with 
the greatest risk shown in the Interphone 
study—the ORs of about 4 within 5 years 
of first use for individuals using a phone for 
≥1,640 hr cumulatively—or with the risk esti-
mates using a “low user” baseline group, given 
in the appendix of the Interphone report 
(Interphone Study Group 2010).
The Interphone levels of exposure were 
those in the population in 2003 and ear-
lier; since then, prevalence and probably 
levels of use have increased greatly. Future 
examination of cancer incidence trend data 
over the next few years, especially by age of 
occurrence and anatomic location of tumors, 
should greatly clarify whether mobile phones 
cause brain tumors: If there are no apparent 
effects on trends in the next few years, after 
almost universal exposure to mobile phones 
in Western countries, it will become increas-
ingly implausible that there is a material causal 
effect. Conversely, if there are unexplained 
rising trends, this will not in itself prove cau-
sation, but will give a case to be answered. 
Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1103693), shows the 
most recently available data, up to 2009, from 
Sweden, one of the earliest adopters of mobile 
phones (see Supplemental Material, Figure 2); 
the data give evidence against an impact of 
mobile phone use on brain tumor occurrence.
Conclusions
Interphone is an impressively large study 
with multiple indices of exposure. However, 
it has some methodological deficits, largely 
inevitable in recall-based case–control studies, 
which limit interpretation of its findings. 
Such evidence as it provides, combined with 
the results of biological and animal studies, 
other epidemiologic studies, and brain tumor 
incidence trends, suggest that within the first 
10–15 years after first mobile phone use there 
is unlikely to be a material increase in risk 
of adult brain tumors resulting from mobile 
phone use. At present there are no data on 
risk of childhood tumors.
The deficiencies of exposure measurement, 
because of recall misclassification in studies 
such as Interphone, and because of misidenti-
fication of users in records-based studies such 
as the published cohorts, leave it doubtful that 
either study type could reliably detect a small 
effect, if one existed. Both for this reason and 
because research cannot in principle prove 
the complete absence of an effect but only 
place limits on its possible magnitude, there is 
bound to remain some uncertainty for many 
years to come. The limited duration of data yet 
available, which is mainly for up to 10 years of 
exposure and to a lesser extent for a few years 
beyond this, also leave uncertainty because 
of the potential for long lag period effects, 
especially for meningioma, which is generally 
slower growing than glioma. The possibility 
of a small or a longer-term effect thus cannot 
be ruled out. Nevertheless, although one can-
not be certain, the trend in the accumulating 
evidence is increasingly against the hypothesis 
that mobile phone use causes brain tumors.
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